News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Yuanyuan Zhang

Articles by Yuanyuan Zhang

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

18 Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Palbociclib in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Phase 1b Cohort

ByErika P. Hamilton, MD,Rinath M. Jeselsohn,Sara A. Hurvitz, MD,Dejan Juric,Hyo S Han,Melinda L. Telli, MD,George Zahrah,Rita Nanda, MD,Yuanyuan Zhang,Weiwei Tan,Elizabeth Duperret,Eric Zhi,Cecile Mather,Anne F. Schott, MD

August 10th 2024

Latest Updated Articles

Trending on CancerNetwork

Did ASCO 2026 Deliver on Its Biggest Pre-Meeting Predictions?

Why CELMoDs Pair Synergistically With PIs and CD38 Antibodies in Multiple Myeloma

26 A Nomogram for Predicting High Axillary Disease Burden in Patients With Localized HR+, HER2-Negative Breast Cancer Following Neoadjuvant Chemotherapy

27 Transfusion and Anemia Management Strategies in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Literature Review

Genomic Prostate Score Identifies Biologically Low-Risk Disease